Rhythm Pharmaceuticals Inc
(NAS:RYTM)
$
55.59
-0.95 (-1.68%)
Market Cap: 3.47 Bil
Enterprise Value: 3.14 Bil
PE Ratio: 0
PB Ratio: 308.96
GF Score: 58/100 Rhythm Pharmaceuticals Inc at Bank of America Healthcare Conference Transcript
May 12, 2022 / 12:20AM GMT
Release Date Price:
$3.44
(+0.29%)
Daniel Giraldo Perez
BofA Securities, Research Division - Associate
Thank you for joining us on the last session of day 2 of the Bank of America Healthcare Conference. My name is Daniel Giraldo. I'm one of the associates in the smidcap biotech team at BofA. And joining me today is David Meeker, CEO of RHythm Pharmaceuticals. Welcome David. Thank you for joining us today.
David P. Meeker
Rhythm Pharmaceuticals, Inc. - Chairman, President & CEO
Thank you, Daniel.
Questions & Answers
Daniel Giraldo Perez
BofA Securities, Research Division - Associate
So maybe we can start by you giving us a brief overview of the company and maybe highlight key catalysts coming up in the next 12 months?
David P. Meeker
Rhythm Pharmaceuticals, Inc. - Chairman, President & CEO
Yes. Sure. So Rhythm is a relatively small biotechnology company focused on rare genetic diseases of obesity. The -- we work on a pathway in the brain called the melanocortin-4 pathway, which
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot